-
Ocrelizumab, sold
under the
brand name Ocrevus, is a
medication used for the
treatment of
multiple sclerosis. It is a
humanized anti-CD20
monoclonal antibody...
-
approved medications continue to emerge. In
March 2017, the FDA
approved ocrelizumab as a
treatment for
primary progressive MS in adults, the
first drug to...
-
Ocrelizumab/hyaluronidase, sold
under the
brand name
Ocrevus Zunovo, is a fixed-dose
combination medication used for the
treatment of
multiple sclerosis...
-
Research (2020-01-24). "New Drug
Therapy Approvals 2019". FDA. "Ocrevus (
ocrelizumab) Injection". www.accessdata.fda.gov.
Retrieved 2021-07-01. "Search Orphan...
-
monoclonal treatment, in
managing this disease,
other anti-CD20
drugs such as
ocrelizumab, veltuzumab, and
ofatumumab have been
explored as
potential treatments...
- and
their approval status: CD20 is the
target of the mAbs rituximab,
ocrelizumab, obinutuzumab, ofatumumab,
ibritumomab tiuxetan, tositumomab, and ublituximab...
- deficiency,
later discontinued in 2004 and
replaced by
Nutropin AQ.
Ocrevus (
ocrelizumab), for MS. Peginterferon/alfa-2a|Pegasys]], (peginterferon alfa-2a) for...
-
cancer indication due to
promising phase II results. 2017:
Ocrevus (
ocrelizumab): The
first FDA-approved
therapy that
treats both relapsing-remitting...
-
ocaperidone (INN)
ocfentanil (INN)
ociltide (INN)
ocinaplon (INN)
ocrase (INN)
ocrelizumab (INN)
Ocrevus Zunovo Ocrevus ocrilate (INN)
ocriplasmin (INN) octabenzone...
- has led to some
other anti-CD20
monoclonal antibodies being developed:
ocrelizumab,
humanized (90%-95% human) B cell-depleting agent.
ofatumumab (HuMax-CD20)...
